



## **ASX Announcement**

9 November 2023

# **General Meeting Results**

**Melbourne, Australia, 9 November 2023** – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its General Meeting today are set out in the attached proxy summary.

### **For enquiries, please contact**

Melanie Leydin  
Company Secretary  
+61 3 9692 7222

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

### **About Avecho**

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM®. TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. New additions to the development program include the recently announced application of TPM® to cannabinoids.

See more here - [avecho.com.au](https://avecho.com.au)

**2023 General Meeting  
Thursday 9 November 2023  
Voting Results**

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001 (Cth)* and ASX Listing Rule 3.13.2.

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution		Resolution Type	If s259U applies		S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain
1	Ratification of prior issue of Shares	Ordinary	N/A	P	140,303,453 94.90%	4,374,328 2.96%	3,167,956 2.14%	14,516,763 -	156,905,583 97.29%	4,374,328 2.71%	14,516,763 -	Carried
2	Approval to issue Shares	Ordinary	N/A	P	137,488,005 91.27%	9,976,828 6.63%	3,167,956 2.10%	14,516,763 -	154,090,135 93.92%	9,976,828 6.08%	14,516,763 -	Carried
3	Approval to issue New Options	Ordinary	N/A	P	130,329,397 90.74%	10,039,053 6.99%	3,252,456 2.27%	14,748,646 -	147,016,027 93.61%	10,039,053 6.39%	14,748,646 -	Carried
4(a)	Approval to issue Shares and New Options to Mr Matthew Patrick McNamara (or his nominee)	Ordinary	N/A	P	151,318,022 90.25%	13,165,108 7.85%	3,175,695 1.90%	93,386,350 -	167,927,891 92.73%	13,165,108 7.27%	93,386,350 -	Carried
4(b)	Approval to issue Shares and New Options to Dr Gregory Collier (or his nominee)	Ordinary	N/A	P	236,837,662 91.70%	18,369,663 7.12%	3,047,123 1.18%	6,790,727 -	253,318,959 93.24%	18,369,663 6.76%	6,790,727 -	Carried
5	Approval to issue Broker Options	Ordinary	N/A	P	235,995,413 94.98%	9,271,361 3.73%	3,192,956 1.29%	16,585,445 -	252,622,543 96.46%	9,271,361 3.54%	16,585,445 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.